Skip to search form
Skip to main content
Semantic Scholar's Logo
Create Free Account
You are currently offline. Some features of the site may not work correctly.
A nuclease-stabilized synthetic ribozyme (ribonucleic acid enzyme) with potential anti-angiogenesis activity. Ribozyme RPI.4610 specifically…
National Institutes of Health
Semantic Scholar uses AI to extract papers important to this topic.
An open‐label, phase 2 trial of RPI.4610 (angiozyme) in the treatment of metastatic breast cancer
P. K. Morrow
Corpus ID: 205664965
Serum and plasma levels of vascular endothelial growth factor (VEGF) correlate with prognosis in patients with metastatic breast…
New agents for treatment of advanced transitional cell carcinoma.
Annals of oncology : official journal of the…
Corpus ID: 9007240
The prognosis for any patient with progressive or recurrent invasive transitional cell carcinoma remains poor. In this context…
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
S. Gail Eckhardt
Cancer Chemotherapy and Pharmacology
Corpus ID: 13212090
PurposeRPI.4610 (ANGIOZYME) is a chemically stabilized ribozyme targeting vascular endothelial growth factor receptor 1. The…
Gateways to clinical trials.
Methods and findings in experimental and clinical…
Corpus ID: 27013008
Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the…
News and Comments
Corpus ID: 28040639
Dr J. G. Duncan. Radiological diagnosis of metabolic bone disease. The metabolic bone diseases which were discussed were…
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Terms of Service
ACCEPT & CONTINUE